Last updated on May 2017

Dosing Requirements of Astagraf XL in African American Kidney Transplant Recipients


Brief description of study

Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.

Detailed Study Description

The purpose of this study is to compare the difference in medication dosage and total daily dose necessary of Astagraf XL® in order to reach therapy goal, when taken with other medications that are routinely used for kidney transplantation, which may stop the development of a substance that can cause long-term damage to the transplanted kidney. African American kidney transplant patients aged 18 and above who are underwent a kidney transplant are eligible to participate. The duration of the study is 3 months.

Clinical Study Identifier: NCT02953873

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

James Fleming, PharmD

Medical University of South Carolina
Charleston, SC United States
  Connect »